Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹9 Cr
Revenue (TTM)
₹0 Cr
Net Profit (TTM)
₹0 Cr
ROE
9.6 %
ROCE
11.9 %
P/E Ratio
--
P/B Ratio
2.2
Industry P/E
357.65
EV/EBITDA
192.8
Div. Yield
0 %
Debt to Equity
0
Book Value
₹12.9
EPS
₹-0.1
Face value
10
Shares outstanding
3,054,500
CFO
₹-1.48 Cr
EBITDA
₹1.35 Cr
Net Profit
₹0.60 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Genomic Biotech
| 15.1 | 17.2 | 14.6 | -52.6 | -- | -- | -- |
|
BSE Healthcare*
| -3.4 | -3.2 | -3.5 | 3.6 | 24.9 | 15.6 | 10.6 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
Genomic Biotech
| -69.8 | 103.4 |
|
BSE Small Cap
| -6.6 | 29.0 |
|
BSE Healthcare
| -3.3 | 43.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Genomic Biotech
|
28.4 | 8.7 | 0.5 | 0.0 | 8.3 | -1.1 | -- | 2.2 |
| 165.1 | 2,627.7 | 2,796.8 | 118.8 | 8.1 | 2.3 | 22.1 | 0.4 | |
| 450.7 | 10,732.6 | 3,262.7 | 439.0 | 15.3 | 16 | 24.4 | 3.6 | |
| 53.0 | 190.1 | 133.8 | -0.3 | -0.7 | -0.6 | -- | 1.9 | |
| 163.6 | 7,497.6 | 2,803.3 | 361.8 | 15.5 | 14 | 20.8 | 2.7 | |
| 1,012.5 | 21,325.1 | 2,169.9 | 332.9 | 20.9 | 15.4 | 64.1 | 9.0 | |
| 4,235.0 | 9,706.6 | 878.4 | 240.1 | 33.8 | 73.3 | 40.4 | 25.3 | |
| 38.1 | 564.1 | 0.0 | 1.6 | -- | -0.5 | 350.6 | 21.0 | |
| 24.7 | 56.3 | 51.4 | 4.5 | 22.0 | 5.2 | 12.5 | 0.6 |
No Review & Analysis are available.
Wholesale of agricultural raw materials and live animals
Incorporated
1994
Chairman
--
Managing Director
Yogesh Agrawal
Headquarters
Jhajjar Dist, Haryana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Genomic Valley Biotech Ltd is ₹28.43 (BSE) as of 18-Mar-2026 IST. Genomic Valley Biotech Ltd has given a return of -52.62% in the last 1 years.
Since, TTM earnings of Genomic Valley Biotech Ltd is negative, P/E ratio is not available.
The P/B ratio of Genomic Valley Biotech Ltd is 2.21 times as on 18-Mar-2026, a 15 premium to its peers’ median range of 1.92 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
50.26
|
4.59
|
|
2024
|
698.34
|
2.99
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Genomic Valley Biotech Ltd are Rs 70.89 and Rs 20.10 as of 19-Mar-2026.
Genomic Valley Biotech Ltd has a market capitalisation of ₹ 9 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Genomic Valley Biotech Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.